ArticleScientific reports2026
ELK1 suppressed the progression of vascular dementia via modulating mTOR/CREB/YAP/TFEB signaling induced ferroptosis in hippocampal cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
To investigate the effects of ELK1 on hippocampal cells and its related mechanisms in the progression of vascular dementia (VD). Twenty-seven SD rats were divided into three groups: sham group (n = 9), Model group (n = 9), and Model+ELK1-OE group (n = 9). The VD animal model was established in the Model group by bilateral common carotid artery occlusion (BCCAO). The Morris water maze test was performed to observe the learning and memory abilities of the rats in the three groups. HE staining was used to examine the morphological changes in the hippocampal region, and immunohistochemical staining was conducted to observe the expression levels of ELK1. In the in vitro experiments, hippocampal tissues were isolated from rats in the sham group to prepare hippocampal single-cell suspensions. After different stimuli, Western blot was performed to observe protein expression, flow cytometry for apoptosis was used to assess hippocampal cell apoptosis, and a colorimetric assay kit was employed to detect the Fe2 + levels in the hippocampal cells of each group. In the in vivo experiments, the levels of ELK1 in VD rats were significantly lower than those in the sham group. ELK1 improved the learning and memory abilities of VD rats. After ELK1 intervention, the arrangement of neural cells in the hippocampal region of the rats was more regular, the nucleoli were clearer, the number of glial cells decreased, and the number of inflammatory cells was reduced. In the in vitro experiments, ELK1 promoted the expression of P-mTOR, P-CREB, and nuclear YAP, inhibited the expression of NOX4 and nuclear TFEB, and reduced hippocampal cell apoptosis and Fe2 + content. ELK1 inhibits the progression of vascular dementia by regulating mTOR/CREB/YAP/TFEB signaling-induced ferroptosis in hippocampal cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.